Impact of expert pathology review in skin adnexal carcinoma diagnosis: Analysis of 2573 patients from the French CARADERM network.

Expert pathological review Hair follicle carcinoma Misdiagnosis Rare cancer network Sebaceous carcinoma Skin adnexal carcinoma Sweat gland carcinoma

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
03 2022
Historique:
received: 23 06 2021
revised: 19 10 2021
accepted: 26 11 2021
pubmed: 30 1 2022
medline: 22 4 2022
entrez: 29 1 2022
Statut: ppublish

Résumé

To prospectively assess the impact of expert pathological review of skin adnexal carcinoma diagnosis in France. From 2014 to 2019, 2573 samples from patients with newly diagnosed or suspected skin adnexal carcinomas were reviewed prospectively by expert pathologists through the national CARADERM (CAncers RAres DERMatologiques) network. Changes in diagnosis between referral and expert review were analysed regarding their potential impact on patient care or prognosis. The samples comprised 2205 newly diagnosed adnexal carcinomas, 129 benign adnexal tumours, 136 basal cell carcinomas, 74 squamous cell carcinomas, six cutaneous metastases and 13 other malignancies. There were 930 (42%) sweat gland carcinomas, of which porocarcinoma (261; 11.8%), microcystic adnexal carcinoma (125; 5.7%) and hidradenocarcinoma (109; 4.9%) were the most frequent subtypes; 778 (35%) hair follicle carcinomas, 238 (11%) sebaceous carcinomas and 212 (10%) extramammary Paget diseases/mammary-like anogenital gland adenocarcinomas. A diagnostic change between referral and expert review occurred in 503 (21.3%) patients, significantly higher for cases sent with a provisional diagnosis seeking an expert second opinion (45.7%) than for cases sent with a formal diagnosis (2.8%) (p < .0001). Sweat gland carcinomas were more prone to diagnostic discrepancies than other tumours (p < .0001), including 1.8% of patients with sweat gland carcinoma subtype misclassification with predicted clinical impact. Changes between benign and malignant conditions occurred in 117 samples (5% of patients). The study provides a unique description of the distribution of skin adnexal carcinomas and highlights the importance of expert review for these rare cancers. Optimal clinical management was impacted in a significant proportion of patients.

Identifiants

pubmed: 35090811
pii: S0959-8049(21)01246-6
doi: 10.1016/j.ejca.2021.11.027
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

211-221

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Auteurs

Maxime Battistella (M)

Université de Paris, AP-HP, Pathology Department, Saint-Louis Hospital, INSERM U976, F-75010, Paris, France. Electronic address: maxime.battistella@aphp.fr.

Brigitte Balme (B)

Pathology Department, CHU Lyon Sud, Lyon, France.

Marie-Laure Jullie (ML)

Pathology Department, CHU de Bordeaux, Bordeaux, France.

Ute Zimmermann (U)

Pathology Department, AP-HP, Ambroise-Paré Hospital, Boulogne-Billancourt, France.

Agnès Carlotti (A)

Pathology Department, AP-HP, Cochin Hospital, Paris, France.

Marie Crinquette (M)

Pathology Department, CHU de Lille, Lille, France.

Eric Frouin (E)

Pathology Department, Poitiers University Hospital, Laboratoire Inflammation, Tissus épithéliaux et cytokines, EA4331, Poitiers University, Poitiers, France.

Nicolas Macagno (N)

Aix-Marseille University, APHM, Pathology Department, Timone University Hospital, INSERM U1251, Marseille, France.

Nicolas Ortonne (N)

Pathology Department, AP-HP, Henri-Mondor Hospital, Créteil, France.

Laurence Lamant (L)

Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.

Arnaud de la Fouchardiere (A)

Pathology Department, Centre Léon-Bérard, Lyon, France.

Marie-Hélène Aubriot-Lorton (MH)

Pathology Department, CHU de Dijon, Dijon, France.

Luc Durand (L)

Pathology Department, CHU de Montpellier, Montpellier, France.

Nicolas Josselin (N)

IHP Nantes, CHU de Nantes, Nantes, France.

Frédéric Franck (F)

Pathology Department, CHU de Clermont-Ferrand, Clermont-Ferrand, France.

Denis Chatelain (D)

Pathology Department, CHU d'Amiens, Amiens, France.

Gilles Lemasson (G)

Pathology Department, CHU de Brest, Brest, France.

Marie-Paule Algros (MP)

Pathology Department, CHU de Besançon, Besançon, France.

Anne Durlach (A)

Pathology Department, CHU de Reims, Reims, France.

Marie-Christine Machet (MC)

Pathology Department, CHU de Tours, Tours, France.

Philippe Courville (P)

Pathology Department, CHU de Rouen, Rouen, France.

Amélie Osio (A)

Université de Paris, AP-HP, Pathology Department, Saint-Louis Hospital, INSERM U976, F-75010, Paris, France.

Alice Seris (A)

Dermatology Unit, François Mitterrand Hospital, Pau, France.

Laurent Mortier (L)

Dermatology Department, CHU de Lille, Université de Lille, Lille, France.

Thomas Jouary (T)

Dermatology Unit, François Mitterrand Hospital, Pau, France.

Bernard Cribier (B)

Dermatology and Dermatopathology, University Hospital and Faculty of Medicine, University of Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH